Navigation Links
QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
Date:6/7/2013

GERMANTOWN, Maryland and HILDEN, Germany, June 7, 2013 /PRNewswire/ --


  • Expansion to about 20 validated gene panels will offer customers new opportunities for targeted clinical sequencing in a growing range of indications in cancer and other diseases
  • Driving adoption through ease of use, quality of results and compatibility with existing NGS workflows as well as with QIAGEN NGS platform now in development
  • Integration of Ingenuity Knowledge Base greatly enhances ease and depth of NGS data interpretation, seen as key bottleneck to NGS adoption in clinical research and diagnostics

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced plans to significantly expand its existing portfolio of molecular assays used in next-generation sequencing (NGS) during 2013 as part of its expansion into this fast-growing market and ambitions to provide an ecosystem of products and services designed to drive greater use of this breakthrough technology in clinical research and diagnostics.

QIAGEN is exhibiting its NGS products at the European Society of Human Genetics Conference from June 8-11 in Paris.

The current portfolio of nine GeneRead™ DNAseq panels launched in late 2012 is being expanded to approximately 20 during the course of 2013. QIAGEN is leveraging its deep molecular content and assay portfolio to create these new gene panels for targeted NGS analysis based on the GeneGlobe portfolio of more than 60,000 annotated molecular assays. Initial customer demand has been very strong for these products, which are "universal" and are designed to be used on any NGS platform, and also to integrate seamlessly into the sample-to-result NGS workflow that includes the QIAGEN GeneRe
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
2. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
3. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
4. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
5. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
6. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
7. For Multiple Sclerosis Treatment, Prescriber Base for Genzymes Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
8. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
9. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
10. Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
11. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Elekta (NSE:EKTAb) and Royal ... Christie NHS Foundation Trust ( Manchester, UK ... whose mission is to develop the clinical value of ... system. Such a system would, in principle, improve the ... "The Christie was an essential participant ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... N.J., Nov. 4 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... months ended September 30, 2009, ending the quarter with $67.5 ... million from December 31, 2008. In October 2009, we ... offering costs from an underwritten public offering of 4,945,000 shares ...
... , PARIS, Nov. 4 Alcatel-Lucent (Euronext Paris and ... TeleHealth Manager, a secure and reliable remote patient monitoring ... Drug Administration (FDA) for marketing in the United States. ... supports remote patient monitoring with an easily deployable ...
Cached Medicine Technology:Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 10Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 11Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 12Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 13Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 14U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 2U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 3
(Date:7/22/2014)... The European Bio stimulants Market report defines ... analysis and forecast of revenue. The bio stimulants market ... million in 2013 to $940.6 million by 2018, at ... Browse through the TOC of the Europe Bio stimulants ... analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes ...
(Date:7/22/2014)... 22, 2014 Alliance Storage ... data archiving solutions, has announced the availability of ... archiving solution. The unique new solution merges optical ... on compliant data archiving across all industries including ... The introduction of the new archiving tier permits ...
(Date:7/22/2014)... Murcia have studied the changes in the brain ... that causes difficulties in inhibiting a response in ... unplanned actions without considering the negative consequences. These ... the risk of behavioural problems. , A new ... Murcia analyses whether the connectivity of an infant,s ...
(Date:7/22/2014)... 22, 2014 There’s an old adage ... to the new improvements and enhancements Global Eyeglasses has ... to make lasting impressions while having what they need ... great, everyday. , “We are offering new sports clip ... said Arjun Sagar, CEO of Global Eyeglasses . ...
(Date:7/22/2014)... As part of a multinational, collaborative effort, ... Sinai have helped identify over 100 locations in the ... in the largest genomic study published on any psychiatric ... published online in Nature, point to biological mechanisms and ... new approaches to treating the disorder, which has seen ...
Breaking Medicine News(10 mins):Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 3Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 4Health News:Children's impulsive behaviour is related to their brain connectivity 2Health News:Global Eyeglasses Adds New Products and Enhances Services 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4
... that second twins born at term are at a higher ... than first twins. However, planned caesarean section may prevent such ... born in Scotland between 1995 and 1998. They found significantly ... second twins born at term. No deaths were recorded among ...
... is observed that women are more likely to experience non-specific ... shows that women are less likely to get prompt treatment ... for 'clotbusting' drugs must be given very rapidly if they ... suggest why there could be a delay in diagnosing stroke ...
... be a waste of time. It does little to reduce ... down by stretching was thought to reduce the risk// of ... out to be wrong, but the stretching habit stuck. It ... injury and improve performance”, comments physiotherapist Rob Herbert of the ...
... was observed that the valve helps patients with advanced esophagal ... is difficulty in swallowing. Unfortunately, the cancer is often well ... survival rates it is generally poor and quite often all ... comfortable as possible. ,Part of this involves inserting ...
... to a new research it is observed that a surgically ... The research focuses on draining cerebrospinal fluid. This type of ... procedure was no longer used// when there seemed to be ... Recent studies of this type of shunting on patients with ...
... a new drug may lower the need for blood ... drug, polymerized bovine hemoglobin (HBOC-201),// is delivered intravenously and ... structure of the HBOC-201 is smaller and more mobile ... effectively distribute oxygen throughout the body. ,The study, ...
Cached Medicine News:
The only daily cleaner specially formulated with isopropyl alcohol to help dissolve lipids and oil-based make-up from contact lenses....
Clerz Plus helps retain moisture to relieve dryness and removes protein buildup from your lenses while you wear them for longer wear comfort....
Lens Plus rewetting drops for soft contact lenses....
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
Medicine Products: